Top

Cancer Cell International

Published in:

Open Access 01-12-2024 | Research

Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

Authors: Tingting Cai, Tao Feng, Guangren Li, Jin Wang, Shengming Jin, Dingwei Ye, Yiping Zhu

Published in: Cancer Cell International | Issue 1/2024

Abstract

Background

Bladder cancer (BCa) stands out as a prevalent and highly lethal malignancy worldwide. Chemoresistance significantly contributes to cancer recurrence and progression. Traditional Tumor Node Metastasis (TNM) stage and molecular subtypes often fail to promptly identify treatment preferences based on sensitivity.

Methods

In this study, we developed a prognostic signature for BCa with uni-Cox + LASSO + multi-Cox survival analysis in multiple independent cohorts. Six machine learning algorithms were adopted to screen out the hub gene, RAC3. IHC staining was used to validate the expression of RAC3 in BCa tumor tissue. RT-qPCR and Western blot were performed to detect and quantify the mRNA and protein levels of RAC3. CCK8, colony formation, wound healing, and flow cytometry analysis of apoptosis were employed to determine cell proliferation, migration, and apoptosis. Molecular docking was used to find small target drugs, PIK-75. 3D cell viability assay was applied to evaluate the ATP viability of bladder cancer organoids before and after PIK-75 treated.

Results

The established clinical prognostic model, GIRS, comprises 13 genes associated with gemcitabine resistance and immunology. This model has demonstrated robust predictive capabilities for survival outcomes across various independent public cohorts. Additionally, the GIRS signature shows significant correlations with responses to both immunotherapy and chemotherapy. Leveraging machine learning algorithms, the hub gene, RAC3, was identified, and potential upstream transcription factors were screened through database analysis. IHC results showed that RAC3 was higher expressed in GEM-resistant BCa patients. Employing molecular docking, the small molecule drug PIK-75, as binding to RAC3, was identified. Experiments on cell lines, organoids and animals validated the biological effects of PIK-75 in bladder cancer.

Conclusions

The GIRS signature offers a valuable complement to the conventional anatomic TNM staging system and molecular subtype stratification in bladder cancer. The hub gene, RAC3, plays a crucial role in BCa and is significantly associated with resistance to gemcitabine. The small molecular drug, PIK-75 having the potential as a therapeutic agent in the context of gemcitabine-resistant and immune-related pathways.

Available only for authorised users

Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81:75–94. https://doi.org/10.1016/j.eururo.2021.08.010.CrossRefPubMed

Porta-Pardo E, Godzik A. Mutation drivers of immunological responses to cancer. Cancer Immunol Res. 2016;4:789–98. https://doi.org/10.1158/2326-6066.CIR-15-0233.CrossRefPubMedPubMedCentral

Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26:1364–70. https://doi.org/10.1200/JCO.2007.12.9791.CrossRefPubMed

Kerr KF, Brown MD, Zhu K, Janes H (2016) Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol: Off J Am Soc Clin Oncol 34(21):2534–2540. https://doi.org/10.1200/JCO.2015.65.5654CrossRefPubMedPubMedCentral

Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong C-W, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022;107: 106936. https://doi.org/10.1016/j.ijsu.2022.106936.CrossRefPubMed

Zhang Y-Y, Li X-W, Li X-D, Zhou T-T, Chen C, Liu J-W, Wang L, Jiang X, Wang L, Liu M, et al. Comprehensive analysis of anoikis-related long non-coding RNA immune infiltration in patients with bladder cancer and immunotherapy. Front Immunol. 2022. https://doi.org/10.3389/fimmu.2022.1055304.CrossRefPubMedPubMedCentral

Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019;20:4331. https://doi.org/10.3390/ijms20184331.CrossRefPubMedPubMedCentral

Hodge RG, Ridley AJ. Regulating rho GTPases and their regulators. Nat Rev Mol Cell Biol. 2016;17:496–510. https://doi.org/10.1038/nrm.2016.67.CrossRefPubMed

Cheng C, Song D, Wu Y, Liu B. RAC3 promotes proliferation, migration and invasion via PYCR1/JAK/STAT signaling in bladder cancer. Front Mol Biosci. 2020;7:218. https://doi.org/10.3389/fmolb.2020.00218.CrossRefPubMedPubMedCentral

10.

Donnelly SK, Cabrera R, Mao SPH, Christin JR, Wu B, Guo W, Bravo-Cordero JJ, Condeelis JS, Segall JE, Hodgson L. Rac3 regulates breast cancer invasion and metastasis by controlling adhesion and matrix degradation. J Cell Biol. 2017;216:4331–49. https://doi.org/10.1083/jcb.201704048.CrossRefPubMedPubMedCentral

11.

Palma AG, Soares Machado M, Lira MC, Rosa F, Rubio MF, Marino G, Kotsias BA, Costas MA. Functional relationship between CFTR and RAC3 expression for maintaining cancer cell stemness in human colorectal cancer. Cell Oncol (Dordr). 2021;44:627–41. https://doi.org/10.1007/s13402-021-00589-x.CrossRefPubMed

12.

Wang L, Shi J, Liu S, Huang Y, Ding H, Zhao B, Liu Y, Wang W, Yang J, Chen Z. RAC3 inhibition induces autophagy to impair metastasis in bladder cancer cells via the PI3K/AKT/mTOR pathway. Front Oncol. 2022;12: 915240. https://doi.org/10.3389/fonc.2022.915240.CrossRefPubMedPubMedCentral

13.

Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. Epidemiology, screening, and prevention of bladder cancer. Eur Urol Oncol. 2022;5:628–39. https://doi.org/10.1016/j.euo.2022.10.003.CrossRefPubMed

14.

Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73:560–9.CrossRefPubMed

15.

Zhang Q, Tan Y, Zhang J, Shi Y, Qi J, Zou D, Ci W. Pyroptosis-related signature predicts prognosis and immunotherapy efficacy in muscle-invasive bladder cancer. Front Immunol. 2022;13: 782982. https://doi.org/10.3389/fimmu.2022.782982.CrossRefPubMedPubMedCentral

16.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle invasive bladder cancer. Cell. 2017;171:540-556.e25. https://doi.org/10.1016/j.cell.2017.09.007.CrossRefPubMedPubMedCentral

17.

Zhou R, Liang J, Tian H, Chen Q, Yang C, Liu C. An immunosenescence-related gene signature to evaluate the prognosis, immunotherapeutic response, and cisplatin sensitivity of bladder cancer. Dis Marker. 2022;2022: e2143892. https://doi.org/10.1155/2022/2143892.CrossRef

18.

Lee S, Gornitz N, Xing EP, Heckerman D, Lippert C. Ensembles of lasso screening rules. IEEE Trans Pattern Anal Mach Intell. 2018;40:2841–52. https://doi.org/10.1109/TPAMI.2017.2765321.CrossRefPubMed

19.

Sjödahl G, Lauss M, Lövgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18:3377–86. https://doi.org/10.1158/1078-0432.CCR-12-0077-T.CrossRefPubMed

20.

Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15:615–25. https://doi.org/10.1038/s41585-018-0055-4.CrossRefPubMed

21.

Wu Z, Liu J, Dai R, Wu S. Current status and future perspectives of immunotherapy in bladder cancer treatment. Sci China Life Sci. 2021;64:512–33. https://doi.org/10.1007/s11427-020-1768-y.CrossRefPubMed

22.

Ranganathan S, Riveros C, Xu J, Geng M, Huang E, Anis M, Muhammad T, Zhang J, Efstathiou E, Wallis CJ, Sonpavde GP. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: a large real-world experience. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.2023.41.6_suppl.477?af=R.CrossRef

23.

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY-S, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:931–45. https://doi.org/10.1016/S1470-2045(21)00152-2.CrossRefPubMed

24.

Gu J, Mao W, Ren W, Xu F, Zhu Q, Lu C, Lin Z, Zhang Z, Chu Y, Liu R, et al. Ubiquitin-protein ligase E3C maintains non-small-cell lung cancer stemness by targeting AHNAK-p53 complex. Cancer Lett. 2019;443:125–34. https://doi.org/10.1016/j.canlet.2018.11.029.CrossRefPubMed

25.

Lee H, Kim K, Woo J, Park J, Kim H, Lee KE, Kim H, Kim Y, Moon KC, Kim JY, et al. Quantitative proteomic analysis identifies AHNAK (neuroblast differentiation-associated protein AHNAK) as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. Mol Cell Proteomics. 2018;17:1788–802. https://doi.org/10.1074/mcp.RA118.000562.CrossRefPubMedPubMedCentral

26.

Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H, Miyamoto H. Cyclosporine a and tacrolimus inhibit bladder cancer growth through down-regulation of NFATc1. Oncotarget. 2015;6:1582–93. https://doi.org/10.18632/oncotarget.2750.CrossRefPubMedPubMedCentral

27.

Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381–97. https://doi.org/10.1002/sim.5958.CrossRefPubMed

Title: Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75
Authors: Tingting Cai
Tao Feng
Guangren Li
Jin Wang
Shengming Jin
Dingwei Ye
Yiping Zhu
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Cancer Cell International / Issue 1/2024
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-024-03258-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Exosome-mediated secretion of miR-127-3p regulated by RAB27A accelerates metastasis in renal cell carcinoma

Correction: Exploring the anti-cancer potential of Ganoderma Lucidum polysaccharides (GLPs) and their versatile role in enhancing drug delivery systems: a multifaceted approach to combat cancer

MicroRNA expression signature as a biomarker in the diagnosis of nodal T-cell lymphomas

Delineating three-dimensional behavior of uveal melanoma cells under anchorage independent or dependent conditions

Influential upregulation of KCNE4: Propelling cancer associated fibroblasts-driven colorectal cancer progression

PI3K/AKT pathway as a pivotal regulator of epithelial-mesenchymal transition in lung tumor cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer